Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
NCT ID: NCT00580125
Last Updated: 2012-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
164 participants
INTERVENTIONAL
2007-11-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
NCT01175135
Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study
NCT03289026
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
NCT00460512
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers
NCT01511510
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00080327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A2
PF-00217830
PF-00217830 5 mg, oral capsule, once daily for 21 days
A5
Placebo
Placebo, oral capsule, once daily for 21 days
A4
Aripiprazole
Aripiprazole 15 mg, oral capsule, once daily for 21 days
A3
PF-00217830
PF-00217830 15 mg, oral capsule, once daily for 21 days
A1
PF-00217830
PF-00217830 2 mg, oral capsule, once daily for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-00217830
PF-00217830 5 mg, oral capsule, once daily for 21 days
Placebo
Placebo, oral capsule, once daily for 21 days
Aripiprazole
Aripiprazole 15 mg, oral capsule, once daily for 21 days
PF-00217830
PF-00217830 15 mg, oral capsule, once daily for 21 days
PF-00217830
PF-00217830 2 mg, oral capsule, once daily for 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Increase in symptoms over the past 2-4 weeks.
* Willing to remain inpatients for the duration of the trial.
Exclusion Criteria
* Subjects who meet the DSM-IV criteria for psychoactive substance abuse and dependence
* Subjects with a history of treatment resistant schizophrenia
* Females of childbearing potential
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Garden Grove, California, United States
Pfizer Investigational Site
Torrance, California, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Bridgeton, Missouri, United States
Pfizer Investigational Site
Florissant, Missouri, United States
Pfizer Investigational Site
Saint Charles, Missouri, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Bangalore, Karnataka, India
Pfizer Investigational Site
Mangalore, Karnataka, India
Pfizer Investigational Site
Udupi, Karnataka, India
Pfizer Investigational Site
Pune, Maharashtra, India
Pfizer Investigational Site
Pune, , India
Pfizer Investigational Site
Gatchina District, Leningradskaya Oblast', Russia
Pfizer Investigational Site
Khot'kovo, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Simferopol, Autonomous Republic of Crimea, Ukraine
Pfizer Investigational Site
Kiev, Ukraine, Ukraine
Pfizer Investigational Site
Dnipropetrovsk, , Ukraine
Pfizer Investigational Site
Donetsk, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kharkiv, , Ukraine
Pfizer Investigational Site
Kyiv, , Ukraine
Pfizer Investigational Site
Luhansk, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A7251006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.